FibroTest-FibroSURE(TM): towards a universal biomarker of liver fibrosis?

Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and superior benefit/risk ratio to biopsy of two combinations of simple serum biochemical markers In patients Infected with hepatitis B and C virus. These Include FibroTest (TM) (BioPredictive) for the quantitative assessment of fibrosis, and ActTest (TM) (BioPredictive) for the quantitative assessment of necroinflammatory activity (HCV-FibroSURE (TM), LabCorp). The possible causes of false negatives and positives are also better Identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases.